skip to content
Primary navigation


Drug - Symproic (naldemedine) [Purdue Pharma]

March 2018

Therapeutic Area - Opioid induced constipation

Approval criteria

  • Patient is at least 18 years old AND
  • Patient is diagnosed with opioid-induced constipation (OIC) related to chronic non-cancer pain AND
  • Patient is currently on opioids AND
  • Patient has been using opioids for at least 75 days within past 90 days AND
  • Patient has not tolerated or has had inadequate response to one-month trials of a stimulant laxative (e.g., bisacodyl; sennosides) AND polyethylene glycol 3350 OR other osmotic laxative (e.g., sorbitol, lactulose, magnesium citrate, magnesium hydroxide, glycerin rectal suppositories) as documented in pharmacy fill history or other documentation indicating fill/refill history if patient is new to Medical Assistance and pharmacy claims data is not readily available AND
  • Patient has not tolerated or has had inadequate response to a one-month trial of Amitiza OR
  • If patient’s OIC is due to diphenylheptane opioids (e.g., methadone); patient must have failed a one-month trial of Movantik AND
  • Patient does not have ANY of the following conditions:
    • Known or suspected gastrointestinal obstruction OR
    • Pregnancy OR
    • Severe hepatic impairment (Child-Pugh Class C)

Quantity limits

34 tablets per 34 days 


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top